Literature DB >> 9059264

Short term immunosuppressive therapy and long-term immunoregulation: promises and problems.

J Isaacs1, A Dick.   

Abstract

Mesh：

Substances：

Year:  1996        PMID： 9059264      PMCID： PMC505697          DOI： 10.1136/bjo.80.12.1035

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN： 0007-1161            Impact factor:   4.638


× No keyword cloud information.
  10 in total

Review 1.  Reprogramming the immune system for peripheral tolerance with CD4 and CD8 monoclonal antibodies.

Authors:  S P Cobbold; S Qin; L Y Leong; G Martin; H Waldmann
Journal:  Immunol Rev       Date:  1992-10       Impact factor: 12.988

Review 2.  Mechanisms of peripheral tolerance and suppression induced by monoclonal antibodies to CD4 and CD8.

Authors:  S P Cobbold; E Adams; S E Marshall; J D Davies; H Waldmann
Journal:  Immunol Rev       Date:  1996-02       Impact factor: 12.988

Review 3.  The possible impact of uveitis in blindness: a literature survey.

Authors:  M S Suttorp-Schulten; A Rothova
Journal:  Br J Ophthalmol       Date:  1996-09       Impact factor: 4.638

4.  Prevention of immune-mediated corneal graft destruction with the anti-lymphocyte monoclonal antibody, CAMPATH-1H.

Authors:  D K Newman; J D Isaacs; P G Watson; P A Meyer; G Hale; H Waldmann
Journal:  Eye (Lond)       Date:  1995       Impact factor: 3.775

5.  Monoclonal antibody therapy of chronic intraocular inflammation using Campath-1H.

Authors:  J D Isaacs; G Hale; H Waldmann; A D Dick; R Haynes; J V Forrester; P Watson; P A Meyer
Journal:  Br J Ophthalmol       Date:  1995-11       Impact factor: 4.638

6.  "Infectious" transplantation tolerance.

Authors:  S Qin; S P Cobbold; H Pope; J Elliott; D Kioussis; J Davies; H Waldmann
Journal:  Science       Date:  1993-02-12       Impact factor: 47.728

7.  Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy.

Authors:  C M Lockwood; S Thiru; J D Isaacs; G Hale; H Waldmann
Journal:  Lancet       Date:  1993-06-26       Impact factor: 79.321

8.  Inhibition of tumor necrosis factor activity minimizes target organ damage in experimental autoimmune uveoretinitis despite quantitatively normal activated T cell traffic to the retina.

Authors:  A D Dick; P G McMenamin; H Körner; B J Scallon; J Ghrayeb; J V Forrester; J D Sedgwick
Journal:  Eur J Immunol       Date:  1996-05       Impact factor: 5.532

9.  The induction of skin graft tolerance in major histocompatibility complex-mismatched or primed recipients: primed T cells can be tolerized in the periphery with anti-CD4 and anti-CD8 antibodies.

Authors:  S P Cobbold; G Martin; H Waldmann
Journal:  Eur J Immunol       Date:  1990-12       Impact factor: 5.532

10.  Low-dose cyclosporin therapy of ocular inflammation: preliminary report of a long-term follow-up study.

Authors:  H M Towler; S L Lightman; J V Forrester
Journal:  J Autoimmun       Date:  1992-04       Impact factor: 7.094
  10 in total
  3 in total

Review 1.  Immunomodulation of autoimmune responses with monoclonal antibodies and immunoadhesins: treatment of ocular inflammatory disease in the next millennium.

Authors:  A D Dick; J D Isaacs
Journal:  Br J Ophthalmol       Date:  1999-11       Impact factor: 4.638

2.  Uveitogenic epitopes of retinal S-antigen are generated in vivo via an alternative antigen-presentation pathway.

Authors:  J Liversidge; R Dawson; A D Dick; J V Forrester
Journal:  Immunology       Date:  1998-06       Impact factor: 7.397

Review 3.  Immunosuppressive therapy for chronic uveitis: optimising therapy with steroids and cyclosporin A.

Authors:  A D Dick; M Azim; J V Forrester
Journal:  Br J Ophthalmol       Date:  1997-12       Impact factor: 4.638
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.